ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FAB Fusion Antibodies Plc

3.35
0.00 (0.00%)
Last Updated: 12:19:16
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.35 3.20 3.50 3.35 3.15 3.35 2,434,699 12:19:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0272 -1.23 3.19M
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.35p. Over the last year, Fusion Antibodies shares have traded in a share price range of 3.10p to 9.875p.

Fusion Antibodies currently has 95,365,564 shares in issue. The market capitalisation of Fusion Antibodies is £3.19 million. Fusion Antibodies has a price to earnings ratio (PE ratio) of -1.23.

Fusion Antibodies Share Discussion Threads

Showing 3826 to 3847 of 4100 messages
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older
DateSubjectAuthorDiscuss
04/12/2023
07:57
No one holds this stock on a spread bet or on a cfd. Therefore the drop is at no loss to us and is a huge buying opportunity.
luckyabbeygale
01/12/2023
10:03
Good find Thiopia and thanks.
mcbull
30/11/2023
16:48
See header thiopia :-)
lawson27
30/11/2023
14:40
Googling 'Mammalian Cell Display' brings up the name of a long time academic researcher on the area dating back to 2009 in terms of published research... Mitchell Ho

Guess who is the Director of the Research on Antibody Engineering (Mammalian Cell Display) at US NCI and on the Fusion Antibodies FAB RNS ? Mitchell Ho !!!

I think people are underestimating just how big a deal this could be for FAB

US Govt NCI just provides one level of validation but an important on (as well as having a multi-billion budget) but this should lead to lots of Bios and Pharmas also beating a path to FAB's door

thiopia
30/11/2023
12:31
Only have to look at the chart to see how much the share price has been squeezed down that RNS was a game changer
bobaxe1
30/11/2023
12:14
I wonder if they will go past 9p again this time round.
luckyabbeygale
29/11/2023
12:55
I nearly brought yesterday, but managed to control my FOMO for once. It's good news though.
montyhedge
29/11/2023
12:53
Good news, but no revenue in rns.
montyhedge
29/11/2023
09:46
Apta is next ;) news due very soon
goldennuggets87
29/11/2023
09:34
Watch out for another cash raise, as they might need it to take the project forward.

DYOR.

clocktower
29/11/2023
09:18
I know, I've had a buy order in for the last hour through trading 212 which hasn't been filled
ih_732280
29/11/2023
09:16
It's only 4 mill mcap ridiculous with collaboration with largest cancer research facility in world with multimillion funding just think where this can go from here where else would you find better to invest hold on for gold here
mally6
29/11/2023
08:08
Not trading for 15 mins, what's that about?
ih_732280
29/11/2023
07:37
Get ready for take off 🚀🚀🚀🚀 8640;
smraynot
28/11/2023
22:25
NCI is operating under a continuing resolution (CR) that provides funding from October 1, 2023 through February 2, 2024, at the same level as fiscal year 2023. The Consolidated Appropriations Act, 2023, allocated $7.3 billion to NCI, including $216 million for the NCI component of the Cancer Moonshot?.20 Nov 2023
mally6
28/11/2023
22:17
NCI RevenueNeo-Concept International Group Holdings had revenue of $233.10M in the twelve months ending June 30, 2023. In the year 2022, Neo-Concept International Group Holdings had annual revenue of $347.45M with 44.45% growth.Revenue (ttm)233.10M HKDRevenue Growth+44.45%Collaboration with nci is 2024 projected funding is in the billions
mally6
28/11/2023
19:25
Volume on breakout of the 50 Day Moving Average is huge

Scope for a lot more upside on the chart with 200 day Moving Average another 100%+ higher than today's closing price

thiopia
28/11/2023
17:53
FAB raised abt £1.56m in May/June this year (2023).
It was an issue of 33.439m shares at a rock-bottom price of only 5p and the reason was the need for capital.

f.

fillipe
28/11/2023
16:26
Difficult to get in any size, market orders only!
lawson27
28/11/2023
16:25
No placing is at 10p
firestarter1
28/11/2023
16:15
Broker offered placing for 5p again soon rns
firestarter1
28/11/2023
15:25
superg118 Sep '20 - 11:01 - 217 of 3633
0 2 1
Tidy

FAB is not yet on the map as such but will be in the coming week or so.

Most booing in now won;t have adman clue about FAB they will assume big cash needed which is completely wrong. That's what I love about FAB.

Very low risk, very big upside...
----
price was 1.2op & itCrashed like crUshed candIes pmsl lYingCnTs

andymunchkin
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older

Your Recent History

Delayed Upgrade Clock